IPN60090   Click here for help

GtoPdb Ligand ID: 12712

Synonyms: Compound 27 [PMID: 33118821] | IACS-6274 | IACS6274 | IPN-60090
Compound class: Synthetic organic
Comment: IPN60090 (a.k.a. IACS-6274) is an inhibitor of the metabolic enzyme glutaminase (GLS), that blocks conversion of glutamine into glutamate [1]. This action inhibits proliferation of rapidly growing tumour cells and promotes their death. IPN60090 was developed as an orally bioavailable agent with antineoplastic potential.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 2
Rotatable bonds 13
Topological polar surface area 132.47
Molecular weight 532.52
XLogP 2.24
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=NC(=CC(=C1)OC2CC(C2)(F)F)CC(=O)NC3=CC=C(CC[C@H](CN4C=C(C(=O)NC)N=N4)F)N=N3
Isomeric SMILES O=C(CC1=CC(OC2CC(F)(F)C2)=CC(C)=N1)NC3=NN=C(CC[C@@H](F)CN4C=C(C(NC)=O)N=N4)C=C3
InChI InChI=1S/C24H27F3N8O3/c1-14-7-18(38-19-10-24(26,27)11-19)8-17(29-14)9-22(36)30-21-6-5-16(31-33-21)4-3-15(25)12-35-13-20(32-34-35)23(37)28-2/h5-8,13,15,19H,3-4,9-12H2,1-2H3,(H,28,37)(H,30,33,36)/t15-/m1/s1
InChI Key GEHZIZWHNLQFAS-OAHLLOKOSA-N
No information available.
Summary of Clinical Use Click here for help
IPN60090/IACS-6274 has advanced to clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05039801 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Phase 1 Interventional M.D. Anderson Cancer Center